JSB462

DRUG3 trials

Sponsors

Novartis Pharmaceuticals

Conditions

Metastatic Hormone-sensitive Prostate CancerMetastatic Prostate Cancer (mCRPC)Prostatic Cancer, Castration-Resistant

Phase 1

A Phase I Study of JSB462 (Luxdegalutamide) in Japanese Patients With Metastatic Prostate Cancer

RecruitingNCT07174063

Novartis PharmaceuticalsMetastatic Prostate Cancer (mCRPC)

Start: 2026-01-14End: 2027-06-18Target: 15Updated: 2026-04-02

Phase 2

An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

RecruitingNCT06991556

Novartis PharmaceuticalsMetastatic Hormone-sensitive Prostate Cancer

Start: 2025-07-07End: 2035-10-19Target: 150Updated: 2026-04-02

A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

RecruitingNCT07047118

Novartis PharmaceuticalsProstatic Cancer, Castration-Resistant

Start: 2025-07-03End: 2028-11-04Target: 130Updated: 2026-04-01

Related Papers

Abstract 4615: Preclinical characterization and evaluation of JSB462 (Luxdegalutamide), a novel AR degrader, and its combinations in prostate cancer

Cancer Research2026-04-03